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Abstract
Background: Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in
women are lower than in men. However, it is unknown if 17b-estradiol treatment is sufficient to inhibit
prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells.
Methods: We analyzed the protein expression of urokinase plasminogen activator (uPA), tissue plasminogen
activator (tPA), matrix metallopeptidases (MMPs), plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of
metalloproteinases (TIMPs), and the cellular motility in PGE2-stimulated human LoVo cells. 17b-Estradiol and the
inhibitors including LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor),
SP600125 (JNK1/2 inhibitor), QNZ (NFB inhibitor) and ICI 182 780 were further used to explore the inhibitory
effects of 17b-estradiol on PGE2-induced LoVo cell motility. Student’s t-test was used to analyze the difference
between the two groups.
Results: Upregulation of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and matrix
metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis, and
subsequent malignant tumor. After administration of inhibitors including LY294002, U0126, SB203580, SP600125 or
QNZ, we found that PGE2 treatment up-regulated uPA and MMP-9 expression via JNK1/2 signaling pathway, thus
promoting cellular motility in human LoVo cancer cells. However, PGE2 treatment showed no effects on regulating
expression of tPA, MMP-2, plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of metalloproteinase-1, -2, -3
and -4 (TIMP-1, -2, -3 and -4). We further observed that 17b-estradiol treatment inhibited PGE2-induced uPA, MMP-
9 and cellular motility by suppressing activation of JNK1/2 in human LoVo cancer cells.
Conclusions: Collectively, these results suggest that 17b-estradiol treatment significantly inhibits PGE2-induced
motility of human LoVo colon cancer cells.
Background
Colorectal carcinoma (CRC) is one of the most preva-
lent cancers world-wide [1], and is the secondary leading
cause of cancer-related mortality in the developed coun-
tries [2]. Colon cancer accounts for more than 130,000
new cases per year [3] and causes more than 56,000
deaths per year in United States [4] despite the
advanced chemotherapeutic treatments.
Degradation of extracellular matrix (ECM) is closely
associated the development of malignant tumor. ECM
degradation by extracellular proteinases accelerates the
progress of tumor cell invasion and metastasis [5]. The
proteolytic proteinase systems primarily responsible for
ECM degradation in vivo are matrix metalloproteinase
(MMPs) and plasminogen activator (PA) systems [5,6].
Matrix metalloproteinases (MMPs) are a family of
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include interstitial collagenases, gelatinases, stromelysin,
matrilysin, metalloelastase, and membrane-type MMPs
[7,8]. Upregulation of MMP-2 and MMP-9 has been
shown to play a key role in the progression, invasion,
metastasis of colorectal cancer in animal models and
patients [9]. MMP activity is closely controlled by phy-
siological inhibitors, TIMPs including TIMP-1, -2, -3
and -4 [10]. Another proteolytic plasminogen system
with its plasminogen activators (PA), such as urokinase-
type plasminogen activators (uPA) and tissue-type plas-
minogen activators (tPA) is showed to activate MMPs
and to be involved in colon cancer progression [11].
Upregulation of uPA and tPA is considered as a marker
of several types of malignant cancer including colon
cancer [12].
Epidemiological studies demonstrate that the inci-
dence and mortality rates of colorectal cancer in women
are lower than in men [13]. Estrogen (E2)p e r f o r m st h e
p r o f o u n de f f e c t so nt a r g e tt i s s u ei sm e d i a t e db yt w o
estrogen receptor (ER) subtypes ERa and ERb [14]. ERa
and ERb have been identified in colon tissue in both
sexes [15]. In observational studies, estrogen exerts a
protective role against the development of fatal colon
cancer with a substantially decreased risk in women
receiving hormone replacement therapy (HRT) [16-18],
and a reduced mortality from this disease [19]. However,
the precise mechanism behind protective effects of 17b-
estradiol against PGE2-induced progression in colon
cancer remains unclear. In the present study, we exam-
ined the effects of 17b-estradiol on PGE2-induced cellu-
lar motility in human LoVo colon cancer cells, and
further identified the precise molecular and cellular
mechanisms behind this protective property. The results
demonstrated that 17b-estradiol treatment inhibits
PGE2-induced cellular motility and expression of uPA
and MMP-9 by suppressing the activation of JNK1/2 in
LoVo cells. The present study suggests that 17b-estra-
diol presents the properties of anti-cancer by inhibiting
PGE2-induced migration in human LoVo cancer cells.
Materials and Methods
Cells, Antibodies, Reagents and Enzymes
Human colon cancer cell lines, LoVo, were obtained
from the American Tissue Culture Collection (ATCC)
(Rockville, MD, USA). LoVo cells were established from
the metastatic nodule resected from a 56-year-old colon
adenocarcinoma patient. 17b-estradiol (E2)a n dh y d r o -
xyurea were purchased from Sigma (Sigma Chemical
Co., St. Louis, Missouri, USA). Prostaglandins E2
(PGE2) was purchased from CALBIOCHEM (Darm-
stadt, Germany). The LY294002 (PI3K inhibitor), U0126
(MEK1/2 inhibitor), SB203680 (p38 MAPK inhibitor),
SP600125 (JNK inhibitor), and ER antagonist ICI
182,780 (ICI) were purchased from TOCRIS (Ellisville,
Missouri, USA). 6-Amino-4-(4-phenoxyphenylethyla-
mino) quinazoline (QNZ), NFB activation inhibitor
was purchased from Peptides International (Louisville,
Kentucky, USA). We utilized the following antibodies
against JNK1/2, phospho-JNK1/2, uPA, tPA, PAI-1,
MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3 and TIMP-
4 (Santa Cruz Biotechnology, Inc. Santa Cruz, California,
USA); a-tubulin (Lab Vision Corporation, Fremont,
California, USA) as loading control. Goat anti-mouse
IgG antibody conjugated to horseradish peroxidase and
goat anti-rabbit IgG antibody conjugated to horseradish
peroxidase and rabbit anti-goat IgG horseradish peroxi-
dase conjugate were purchased from Santa Cruz Bio-
technology, Inc. in California, USA.
Cell Culture
LoVo colon cancer cell line from the American Type
Culture Collection (ATCC) (Rockville, MD) were cul-
tured on 100-mm or 60-mm culture dishes in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 100 μg/ml penicillin, 100 μg/ml streptomycin, 2
mM glutamine, 1 mM HEPS buffer, and 10% Clontech
fetal bovine serum in humidified air (5% CO2) at 37°C
Immunoblotting
To isolate total proteins, cultured LoVo cells were
washed with cold PBS and resuspended in lysis buffer
(50 mM Tris, pH 7.5, 0.5 M NaCl, 1.0 mM EDTA, pH
7.5, 10% glycerol, 1 mM BME, 1% IGEPAL-630 and a
proteinase inhibitor cocktail (Roche Molecular Biochem-
icals)). After incubation for 30 min on ice, the superna-
tant was collected by centrifugation at 12000 g for 15
min at 4°C, and the protein concentration was deter-
mined by the Bradford method. Sample containing
equal proteins (60 μg) were loaded and analyzed by
Western blot analysis. Briefly, proteins were separated
by 12% SDS-PAGE and transferred onto PVDF mem-
brane (Millipore, Belford, Massachusetts, USA). Mem-
brane were blocked with blocking buffer (5% non-fat
dry milk, 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and
0.1% Tween 20) for at least 1 h at room temperature.
Membranes were incubated with primary antibodies in
the above solution on an orbit shaker at 4°C overnight.
Following primary antibody incubation, membranes
were incubated with horseradish peroxidase-linked sec-
ondary antibodies (anti-rabbit, anti-mouse, or anti-goat
IgG).
Migration Assay
Migration assay was performed using the 48-well Boy-
den chamber (Neuro Probe) plate with the 8-μmp o r e
size polycarbonate membrane filters [20]. The lower
compartment was filled with DMEM containing 20%
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Boyden chamber containing serum-free medium and
incubated for 48 h. After incubation, the cells on mem-
brane filter were fixed with methanol and stained with
0.05% Giemsa for 1 h. The cells on upper surface of the
filter were removed with a cotton swab. The filters were
then rinsed in double distilled water until additional
stain was leached. The cells then were air-dried for 20
min. The migratory phenotypes were determined by
counting the cells that migrated to the lower side of the
filter with microscopy at 200× and 400× magnification,
respectively. The fourth fields were counted for each fil-
ter, and each sample was assayed in triplicate.
Statistical Analysis
Each experiment was duplicated at least three times.
Results were presented as the mean ± SE, and statistical
comparisons were made using the Student’s t test. Sig-
nificance was defined at the p < 0.05 or 0.01 levels.
Results
The Effects of Prostaglandin E2 on Expression of uPA,
tPA, MMP-2 and MMP-9 in Human LoVo Colon Cancer
Cells
We detected the expression of cellular migration-regulat-
ing factors such as urokinase-type plasminogen activators
(uPA), tissue-type plasminogen activators (tPA), matrix
metalloproteinases-2 and -9 (MMP-2 and -9) in LoVo
cells. Activation of proteolytic plasminogen system with
t-PA and u-PA is shown to be involved in upregulation of
MMPs [6]. In the present study, we observed that the
significant increase in expression levels of uPA (Figure 1A)
and MMP-9 (Figure 1B) was induced following PGE2
(10
-6M) treatment within 3 h, and was maintained up for
24 h. The quantitative results showed that uPA was signifi-
cantly increased by approximately 2.47-fold within 3 h,
2.32-fold within 6 h, 2.75-fold within 12 h, and 2.48-fold
within 24 h. MMP-9 was significantly increased by
approximately 2.27-fold within 3 h, 2.52-fold within 6 h,
2.65-fold within 12 h, and 2.79-fold within 24 h. However,
PGE2 treatment showed no effects on protein expression
of tPA and MMP-2.
The Effects of Prostaglandin E2 on the Expression of PAI-
1 and TIMPs in Human LoVo Colon Cancer Cells
uPA and tPA is closely controlled by PAI-1. In addition,
activation of MMP-2 and MMP-9 was inhibited by
TIMPs, therefore we further examined whether the
expression of PAI-1 and TIMPs including TIMP-1, -2, -3,
and -4 was reduced by PGE2 treatment. As shown in
Figure 2, LoVo cells were treated with PGE2 (10
-6M) for
various periods (3 h, 6 h, 12 h and 24 h), and subsequently
subjected to immunoblotting assay. We observed that
A 
 
 
 
 
B 
Figure 1 PGE2 induces expression of uPA and MMP-9 in human
LoVo colon cancer cells. LoVo cells cultured in DMEM were treated
with PGE2 (10
-6M) for 3 h, 6 h, 12 h and 24 h, and subsequently
observed protein level of uPA, tPA (A), MMP-2 and MMP-9 (B) in
LoVo cells by immunoblotting assay. The responses to different time
periods of PGE2 treatment were measured by the immunoblotting
assay. **, p < 0.01 versus control (mean ± SE, n = 3).
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Page 3 of 12Figure 2 The effect of PGE2 on the expression of PAI-1 and TIMPs in human LoVo colon cancer cells. LoVo cells cultured in DMEM were
treated with PGE2 (10
-6M) for 3 h, 6 h,12 h and 24 h, and then were harvested and lysed. Total protein of cell extracts was separated by 12%
SDS-PAGE, transferred to PVDF membranes, and immunoblotted with antibodies against proteins as indicated. Equal loading was assessed with
an anti-a-tubulin antibody.
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TIMP-1, -2, -3, and -4 in human LoVo cells.
JNK1/2 Mediates PGE2-Upregulated uPA and MMP-9 in
Human LoVo Colon Cancer Cells
To further identify which signal transduction pathway(s)
was involved in the mechanism behind PGE2-upregu-
lated expression of uPA and MMP-9 in human colon
cancer cells, we applied the following inhibitors such as
LY294002 (Akt activation inhibitor), U0126 (ERK1/2
activation inhibitor), SB203580 (p38 MAPK inhibitor),
SP600125 (JNK1/2 inhibitor), and QNZ (NFB activa-
tion inhibitor) to respectively block these pathways, fol-
lowed by the administration of PGE2. LoVo cells were
preincubated with LY294002 (1 μM), U0126 (1 μM),
SB203580 (1 μM), SP600125 (1 μM) or QNZ (1 μM) for
1 h and followed by the administration of PGE2 (1 μM)
for 24 h, and subsequently were subjected to immuno-
blotting assay to assess the effect of these inhibitors on
PGE2-induced expression of uPA and MMP-9. We
observed that PGE2-induced expression of uPA and
MMP-9 was significantly inhibited by JNK1/2 inhibitor,
SP600125, in LoVo cells. The results suggested that
PGE2 upregulates expression of uPA and MMP-9 via
JNK1/2 signaling pathway in human LoVo colon cancer
cells (Figure 3A).
To further explore the effects of PGE2 on activation of
JNK1/2 in human LoVo colon cancer cells, we treated
LoVo cells with PGE2 (10
-6M) for various time periods
(15 min, 30 min, 1 h, 3 h, 6 h, 12 h and 24 h), and sub-
sequently measured the phosphorylation/activation of
proteins by immunoblotting assay. Phosphorylation of
JNK1/2 was significantly induced within 15 min in
response to PGE2 stimulation, and was maintained up
for 24 h (Figure 3B). The findings suggested that admin-
istration of PGE2 may induce the motility of human
colon cancer by inducing the activation of JNK1/2.
17b-Estradiol Inhibits PGE2-Induced Expression of uPA
and MMP-9 by Suppressing Activation of JNK1/2
In the present study, we treated LoVo cells with 17b-
estradiol (10
-8M) for various time periods (5 min, 15 min,
3 0m i n ,1h ,3h ,6h ,1 2ha n d2 4h ) ,a n ds u b s e q u e n t l y
measured the phosphorylation/activation of proteins by
immunoblotting assay. The results show that phosphory-
lation of JNK1/2 was significantly reduced within 5 min
in response to 17b-estradiol stimulation, and was main-
tained up for 24 h (Figure 4A). We further examined
whether 17b-estradiol inhibits PGE2-induced expression
of uPA and MMP-9, and identified the related precise/
molecular mechanism in LoVo cells. LoVo cells were pre-
treated with 17b-estradiol (10
-8M) for 30 min, followed
by PGE2 (10
-6M) treatment for 30 min or 24 h, and then
were subjected to immunoblotting assay for protein
detection of phospho-JNK1/2, uPA and MMP-9, respec-
tively. We observed that 17b-estradiol treatment signifi-
cantly inhibits PGE-induced activation of JNK1/2 within
3 0m i n ,a n ds u p p r e s s e dP G E 2 - i n d u c e de x p r e s s i o no f
uPA and MMP-9 within 24 h in human LoVo colon can-
cer cells (Figure 4B).
17b-Estradiol Inhibits PGE2-Induced Cell Migration in
Human LoVo Colon Cancer Cells
In the present study, we examined the effects of PGE2
on the migration ability in human LoVo colon cancer
cells by culturing LoVo cells with PGE2 (10
-6M) in the
presence or absence of JNK1/2 inhibitor (SP600125) for
48 h. Subsequently, we observed the ability of motility
in LoVo cells by migration assay. Because DNA synth-
esis was completely inhibited by hydroxyurea (2 mM), a
ribonucleotide reductase inhibitor, present in the med-
ium, the elevated level in cell migration could not be
ascribed to the increased potential of cell proliferation.
In migration assay (Figure 5), we observed that PGE2
induced a significant increase in cellar migration in
LoVo cells. A significant increase of cell migration about
83.78% following PGE2 treatment (10
-6M) for 48 h was
observed in human LoVo cancer cells. However,
SP600125 significantly blocked PGE2-induced cell
migration about 70.27% when compared with PGE2-
treated group. In addition, pretreatment of 17b-estradiol
(10
-8M) significantly inhibited PGE2-promoted LoVo
cancer cell migration. ICI 182780 treatment further con-
firmed the inhibitory property of 17b-estradiol/estrogen
receptor (ER) complex on LoVo cellular motility by sup-
pressing function of ERs. These findings suggested that
17b-estradiol might inhibit PGE2-promoted cellular
motility by suppressing activation of JNK1/2 in human
LoVo colon cancer cells.
Discussion
The major findings of the present study can be summar-
ized as followings: (1) PGE2 treatment significantly
induced phosphorylation of JNK1/2 in human LoVo
colon cancer cells. (2) Migration of LoVo colon cancer
cells was significantly promoted by PGE2 (10
-6M) treat-
ment. We simultaneously observed that an increase in
cell migration was accompanied with the upregulation
of migration-related factors including uPA and MMP-9,
following PGE2 (10
-6M) treatment. In addition, JNK1/2
mediated PGE2-induced expression of uPA and MMP-9
in LoVo cells. (3) However, PGE2 (10
-6M) treatment
showed no influences on regulating the expression of
PAI-1, TIMP-1, TIMP-2, TIMP-3 and TIMP-4 in LoVo
cells. (4) PGE2-induced expression of uPA and MMP-9
in human LoVo cells was significantly inhibited by 17b-
estradiol (10
-8M) pretreatment. 17b-Estradiol signifi-
cantly inhibited PGE2-induced uPA and MMP-9
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Page 5 of 12Figure 3 PGE2 upregulates uPA and MMP-9 via JNK1/2 signaling pathway in human LoVo colon cancer cells. (A) LoVo cells were
pretreated with vehicle, LY294002 (Akt activation inhibitor), U0126 (ERK1/2 activation inhibitor, 1 μM), SB203580 (p38 MAPK inhibitor, 1 μM),
SP600125 (JNK1/2 inhibitor, 1 μM) or QNZ (NFB inhibitor, 1 μM) for 1 h and followed by PGE2 (10
-6M) administration for 24 h, and then were
harvested for immunoblotting assays. (B) LoVo cells cultured in DMEM were treated with PGE2 (10
-6M) for various periods (15 min, 30 min, 1 h, 3
h, 6 h, 12 h and 24 h), and subsequently measured the phosphorylation/activation of proteins by immunoblotting assay. The fold ratio of p-
JNK1/2 and JNK1/2 was measured. Total protein of cell extracts was separated by 12% SDS-PAGE, transferred to PVDF membranes, and
immunoblotted with antibodies against uPA, MMP-9 (A), phospho-JNK1/2 and JNK1/2 (B) proteins. Equal loading was assessed with an anti-a-
tubulin antibody. **, p < 0.01 versus control (mean ± SE, n = 3).
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results demonstrate that 17b-estradiol may efficiently
inhibit PGE2-induced motility in human LoVo colon
cancer cells (Figure 6).
Upregulation of MMPs is reported to contribute to
ECM remodeling, tumor cell invasion and metastasis, thus
leading to the development of malignant tumor [5]. Both
mRNA levels MMP-2 and MMP-9 have been found to be
overexpressed in colon carcinomas [21,22]. In the observa-
tions of Collins et al. [23], MMP-2 mRNA is more signifi-
cantly expressed in tumor lesions than in normal colon
tissues. Immunostaining assay showed that MMP-9
expression is more frequently present in advanced tumor
stages, and in invasive tumor regions wherein cancer cells
are in close proximity of inflammatory cells, suggesting
that locally proteolytic and collagenlytic activities contri-
butes to the property of invasion in colorectal cancers
[24]. In the stage of cancer development, upregulation of
MMP-2 and MMP-9 accelerates cell migration and inva-
sion in colorectal cancer [9], thus resulting in the develop-
ment of malignant tumor, poor prognosis, and shortening
disease-free period and overall survival. Here, we founded
that administration of 17b-estradiol significantly inhibited
PGE2-induced cell migration, and downregulated PGE2-
upregulated expression of MMP-9 in LoVo cells. The
findings suggested that 17b-estradiol may impair PGE2-
promoted cell motility by inhibiting the expression of
MMP-9.
Figure 4 17b-Estradiol down-regulates PGE2-induced uPA and MMP-9 expression by suppressing activation of JNK1/2 in human LoVo
cells. (A) LoVo cells cultured in DMEM were treated with 17b-estradiol (10
-8M) for various periods (5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h
and 24 h), and subsequently measured the phosphorylation/activation of proteins by immunoblotting assay. The fold ratio of p-JNK1/2 and
JNK1/2 was measured. (B) LoVo cells were pretreated with 17b-estradiol (10
-8M) for 30 min, followed by PGE2 (10
-6M) treatment for 30 min or 24
h, and then were subjected to immunoblotting assay for protein detection of phospho-JNK1/2 (PGE2 stimulation within 30 min); uPA and MMP-
9 (PGE2 stimulation within 24 h).
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Page 7 of 12Figure 5 17b-estradiol inhibits PGE2-promoted cellular motility in human LoVo cells. LoVo cells were pretreated with vehicle, SP600125
(JNK1/2 inhibitor, 1 μM) or 17b-estradiol (10
-8M) for 1 h prior to PGE2 (10
-6M) treatment for another 48 h in hydroxyurea-containing DMEM, and
subsequently observed the ability of migration in LoVo cells by migration assay. At the same time, LoVo cells were treated 17b-estradiol (10
-8M)
in the presence or absence of ERs inhibitor, ICI 182780 (5 × 10
-7M). The responses to different treatments were observed and analysis with a
light microscope. *, p < 0.05 versus control;**, p < 0.01 versus control. ##, p < 0.01 versus PGE2 treatment group (mean ± SE, n = 4).
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upregulation of uPA and tPA is reported to be involved
in MMPs activation and colon cancer development
[11,25]. uPA was significantly greater in tumour tissues
than normal tissues [26]. uPA upregulated in colon
tumor tissue enhances colorectal cancer invasion and
metastasis, and this upregulation in uPA is correlated
with Dukes’s staging and lymphatic invasion [27].
 
Figure 6 A schematic representation showing 17b-estradiol inhibition of uPA and MMP-9 expression, and cell motility via suppression
of JNK1/2 pathway in human LoVo colon cancer cells. Administration of prostaglandin E2 (PGE2) rapidly activates kinase such as JNK1/2,
thus leading to the expression of downstream targets including uPA and MMP-9, which further promotes cellular motility in human LoVo cancer
cells. However, PGE2 treatment shows no effects on regulation of tPA, MMP-2, PAI-1 and TIMPs (TIMP-1, TIMP-2, TIMP-3 and TIMP-4). Estrogen
receptor is activated by 17b-estradiol binding to form 17b-estradiol-ER complex. 17b-Estradiol-ER complex presents the properties of anti-cancer
by downregulating expression of uPA amd MMP-9 via deactivation of JNK1/2 in LoVo cells. It suggests that 17b-estradiol might inhibit PGE2-
induced motility of human LoVo colon cancer cells.
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as a marker malignant colon cancer [11,12]. In the pre-
sent study, we observed that the significant reduction in
protein level of uPA was observed after 17b-estradiol
treatment in human colon cancer cells. These findings
suggested that downregulation of uPA is involved in
17b-estradiol-mediated anticancer effects.
Activation of MMPs is regulated by physiological inhi-
bitors TIMPs [28]. TIMPs not only directly inhibit
MMPs but also form complexes with MMPs to control
activation and stability of MMPs [10,29]. Four different
TIMP species have been identified as TIMP-1, TIMP-2,
TIMP-3 and TIMP-4. TIMP binds to MMP in a 1:1
stoichiometric ratio. Induction of functional TIMP-3 in
TIMP-3-deficient human DLD-1 colon cells shows a
growth arrest and inhibits tumor growth in vivo [30].
Injection of AdTIMP-2 into preestablished tumors pre-
sents the significant reduced tumor growth rates by
approximately 60-80% and tumor-associated angiogen-
esis index by approximately 25-75%. Metastasis of LLC
tumor was inhibited by > 90%. In addition, AdTIMP-2-
treated mice showed a significantly prolonged survival
[31], which emphasizes the importance of endogenous
regulation of MMPs activity by TIMPs. In the present
study, we further detected the protein level of TIMPs in
human LoVo cancer cells that had been exposed to
PGE2, which demonstrated that PGE2 treatment shows
no influence on regulating TIMP-1, TIMP-2, TIMP-3
and TIMP-4. The results suggested that PGE2 couldn’t
promote the motility of colon cancer by down-regulat-
ing expressions of TIMPs. In addition, the proteolytic
action of uPA and tPA is controlled by plasminogen
activator inhibitors 1 and 2 (PAI-1 and PAI-2) [11]. We
thus simultaneously examined the expression of PAI-1
in LoVo cells that had been treated with PGE2. How-
ever, no influence on PAI-1 expression was observed
after PGE2 stimulation.
A large number of studies have been dedicated to
exploring the molecular mechanisms involved in the
downregulation of cancer development. Mitogen-acti-
vated protein kinases (MAPKs) include tree major sub-
families such as the extracellularly responsive kinases
(ERKs), the c-Jun N-terminal kinases (JNKs), also
known as stress-activated protein kinases (SAPKs), and
the p38 MAPKs [32]. Studies have showed that ERK1/2
is involved in hepatoma-derived growth factor-induced
promotion of carcinogenesis of gastric epithelial cells
[33] and in the proliferation of pancreatic stellate cells
[34]. p38 MAPK mediates TNFa-induced MMP-9
expression, thus leading to the progression of human
urinary bladder cancer cells [35]. JNK/AP-1 signaling
pathway may contribute to cellular migration and inva-
sion of prostate cancer cells [36]. Hepatocyte growth
factor-activated both Akt and JNK enhance the
proteolysis and invasiveness of human nasopharyngeal
cancer cells [37]. Abnormal response of NFkB signaling
pathway may contribute to the chemoresistance in acute
lymphoblastic leukaemia [38]. In the present study, we
observed that JNK1/2 signaling pathway mediated
expression of uPA and MMP-9 in response to PGE2,
which further contributed to cellular motility of human
LoVo cancer cells. Previous studies have shown that
17b-estradiol (E2) binding to estrogen receptors (ERs)
can regulate tissue/cellular responses through multiple
signaling pathways [32]. In the present study, we further
observed that 17b-estradiol pretreatment inhibited
PGE2-induced expression of uPA, MMP-9, and cellular
motility via suppressing activation of JNK1/2 in LoVo
cells. It suggested that 17b-estradiol presents the anti-
cancer properties by inhibiting PGE2-promoted motility
in human LoVo cancer cells.
Estrogen receptor a and b (ERa and b) have been
identified in colon tissue [15,39,40]. In the normal colon
mucosa, there are no significant differences in the pro-
tein expression of ERa and b between men and women
[40]. Epidemiological data on taking home replacement
therapy (HRT) suggests that the loss of estrogen inacti-
vation may be an important mechanism in the patho-
genesis of colonic cancer [41]. Studies suggest that
estrogen exerts a protective role against the develop-
ment of fatal colon cancer with a substantially decreased
risk in women receiving HRT [16-18], and a reduced
mortality from this disease [19]. In this study, we
observed that 17b-estradiol reduces PGE2-induced moti-
lity of LoVo colon cancer cells derived from male origin.
The above study findings strongly suggest that estrogen
treatment is an important program against the develop-
ment of colon cancer.
Estrogen has been reported to modulate the activity of
the multiple signaling cascades [42,43] such as the induc-
tion of translocation of ER to the cell membrane in
MCF-7 cells [44], and then E2/ERs complex interact with
caveolin-1/-2 in caveolae regions of the plasma mem-
brane [45] wherein cavelin-1 is associated with signaling
molecules, such as G proteins, growth factor receptors
(IGFIR, EGFR), non-growth factor tyrosine kinase (Src,
Ras), and linker proteins (MNAR, striatin) [46,47]. In
addition, membrane ER can activate Src-MMP2/9-EGFR-
MAPK pathway through Gai protein in breast cancer
cells [47], and activate MAPK-dependent endothelial
nitric oxide synthase (eNOS) to increase NO production,
contributing to the beneficial effects on cardiac cells
[48,49]. In COS7 cell, cytosolic ER binds to membrane
IGF-IR and rapidly activates IGF-IR-Ras-Raf-MAPKK-
ERK1/2 signaling cascade, which in turn activates ER in a
positive feedback loop [50]. In the present study, we
observed that 17b-estradiol (10
-8 M) treatment rapidly
reduces the phosphorylation of JNK1/2 within 15 min. in
Hsu et al. Journal of Biomedical Science 2011, 18:61
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Page 10 of 12human LoVo colon cancer cells, which suggests that
estrogen-membrane ER complex might majorly reduce
PGE2-induced JNK1/2 phosphorylation through non-
genomic effect. Previous studies have reported that ERb
is expressed greater in normal colon tissues than patholo-
gic tissues [51], and that the increased ratio of ERa and b
due to altered expression of ER subtypes is found in
patients with CRC [40], supporting the role of ERb as a
relevant prognostic biomarker of tumor progression [52].
According to these previous studies, we speculated that
17b-estradiol might decrease PGE2-induced cellular
motility through ERb in human LoVo colon cancer cells.
Conclusions
In summary, we found that PGE2 rapidly activates
JNK1/2 kinase, and then increases the protein levels of
uPA and MMP-9, which further promotes cellular moti-
lity in human LoVo cancer cells. 17b-Estradiol presents
the properties of anti-cancer by downregulating expres-
sion of uPA and MMP-9 via deactivation of JNK1/2 in
LoVo cells. These results also demonstrate that 17b-
estradiol efficiently inhibit PGE2-induced LoVo cell
motility. These findings might explain that why the inci-
dence and mortality rates of colorectal cancer in women
are lower than in men; and that estrogen exerts a pro-
tective role against the development of fatal colon can-
cer with a substantially decreased risk in women
receiving hormone replacement therapy (HRT) and a
reduced mortality from this disease.
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